{
    "clinical_study": {
        "@rank": "159644", 
        "acronym": "SAXA", 
        "arm_group": [
            {
                "arm_group_label": "Lower dose", 
                "arm_group_type": "Experimental", 
                "description": "co-administration of a single oral dose of a 5 mg saxagliptin tablet and a 500 mg metformin XR (Glucophage XR\u00ae) tablet vs. single FDC tablet consisting of 5 mg saxagliptin and 500 mg metformin XR (Kombiglyze XR)"
            }, 
            {
                "arm_group_label": "Higher dose", 
                "arm_group_type": "Experimental", 
                "description": "co-administration of a single oral dose of a 5 mg saxagliptin tablet and two (2) 500 mg metformin XR (Glucophage XR\u00ae) tablets vs. Single FDC tablet consisting of 5 mg saxagliptin and 1000 mg metformin XR (Kombiglyze XR)"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of this study is to assess the pharmacokinetic parameters of\n      saxagliptin and metformin in healthy male Chinese subjects."
        }, 
        "brief_title": "A Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "condition": "Type 2 Diabetes Mellitus(T2DM)", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "detailed_description": {
            "textblock": "A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the\n      Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the\n      Individual Components in two cohorts of Healthy Chinese Subjects under Fed Conditions"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Chinese ethnicity which is defined as having both parents and 4 grandparents who are\n             Chinese\n\n          -  Healthy male subjects as determined by no clinically significant deviation from\n             normal in medical history, physical examination, ECGs, and clinical laboratory\n             determinations\n\n          -  Men, ages 18 to 40 years, inclusive. The age difference among the subjects is within\n             10 years\n\n          -  Weigh at least 50 kg and have a body mass index (BMI) between 19 and 24 kg/m2\n\n          -  Sexually active fertile men must use effective birth control throughout the study and\n             for up to 90 days after the last dose of investigational product if their partners\n             are women of child bearing potential\n\n        Exclusion Criteria:\n\n          -  Any significant acute or chronic medical illness\n\n          -  Current or recent gastrointestinal disease\n\n          -  Subjects that have lymphocytopenia or thrombocytopenia\n\n          -  History of autoimmune skin disorder\n\n          -  Estimatedcreatinine clearance of less than 80 mL/min"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "64", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01755494", 
            "org_study_id": "D1681C00001"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Lower dose", 
                    "Higher dose"
                ], 
                "description": "Saxagliptin oral tablet 5mg, single dose", 
                "intervention_name": "Saxagliptin 5 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lower dose", 
                "description": "Metformin XR oral tablet 500 mg, single dose", 
                "intervention_name": "Metformin XR 500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Higher dose", 
                "description": "Metformin XR oral tablet 2 x 500 mg, single dose", 
                "intervention_name": "Mertformin XR 2 x 500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Lower dose", 
                "description": "oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose", 
                "intervention_name": "Komboglyze XR 5/500 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Higher dose", 
                "description": "oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose", 
                "intervention_name": "Komboglyze XR 5/1000 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Saxagliptin", 
                "Metformin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Type 2 diabetes, Saxagliptin, Metformin,Fixed dose combination tablet, Bioequivalence, pharmacokinetic, safety, tolerability", 
        "lastchanged_date": "December 12, 2013", 
        "link": {
            "description": "D1681C00001.pdf", 
            "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1189&filename=D1681C00001.pdf"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-centre, Randomized, Open-label, Two-period, Cross-over, Bioequivalence Study of the Fixed Dose Combinations of Saxagliptin/Metformin XR Relative to Co-Administration of the Individual Components in Two Cohorts of Healthy Chinese Subjects Under Fed Conditions", 
        "overall_official": [
            {
                "affiliation": "Room No.: C3C-718, 1800 Concord Pike, PO Box 15437, Wilmington DE 19850-5437, USA", 
                "last_name": "Boaz Hirshberg", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Peking University Third Hospital (PU3), 49 North Garden Road, Haidian District, Beijing 100191, PR. China", 
                "last_name": "Haiyan Li", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Maximum plasma concentration (Cmax) for saxagliptin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Maximum plasma concentration (Cmax) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Area under plasma concentration time curve (AUC) for saxagliptin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Area under plasma concentration time curve (AUC) for metformin during treatment with fixed dose combination tablet of metformin plus saxagliptin compared with individual metformin XR and saxaglitpin tablets", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01755494"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum plasma concentration (Cmax) for 5-hydroxy saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }, 
            {
                "measure": "Area under plasma concentration time curve (AUC) for 5-hydroxy saxagliptin", 
                "safety_issue": "No", 
                "time_frame": "Plasma samples at 0, 15, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 18, 24, 36 and 48 hours post-dose"
            }, 
            {
                "description": "Assessment for 5 mg saxagliptin co-administered with up to 1000 mg metformin XR given either separately, or as a single FDC tablet.", 
                "measure": "Safety and tolerability assessment based on medical review of AE reports:physical examination, ECG, heart rate, blood pressure, lab test", 
                "safety_issue": "Yes", 
                "time_frame": "Study duration for individual subject (up to 34 days) when the safety data are collected"
            }
        ], 
        "source": "AstraZeneca", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}